Douglas Loe

DOUGLAS LOE is healthcare and biotechnology analyst at Dlouhy Merchant
Group. Dr. Loe has covered the Canadian biotechnology sector since 2000
and joined the Dlouhy team in August 2002. He holds a MBA from Queen’s
University and a PhD in biochemistry from the University of Guelph,
working in the area of cancer chemotherapy and multidrug resistance,
followed by post-doctoral training at the Queen’s University Cancer
Research Laboratories. Prior to commencing his career in financial
analysis, Dr. Loe worked as a consultant to Molecular Mining Corporation
and MDS Inc. To date, Dr. Loe has published 24 abstracts and 17 peer-
reviewed manuscripts and review articles related to P-glycoprotein and
MRP-mediated multidrug resistance.